Study of AZD9574 as monotherapy and in combination with anti-cancer agents in participants with advanced solid malignancies

Trial Identifier: D8410C00001
Sponsor: AstraZeneca
NCTID:: NCT05417594
Start Date: June 2022
Primary Completion Date: January 2026
Study Completion Date: January 2026
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AU Camperdown, AU, 2050
AU Darlinghurst, AU, 2010
AU Melbourne, AU, 3000
AU Randwick, AU, 2031
DE Bayern, DE, 80337
DE Berlin, DE, 13353
DE Heidelberg, DE, 69120
DE Mainz, DE, 55131
ES A Coruña, ES, 15006
ES Barcelona, ES, 8035
ES Pozuelo de Alarcon, ES, 28223
ES Sant Cugat del Valles, ES, 08195
ES Sevilla, ES, 41013
GB Glasgow, Scotland, GB, G12 0YN
GB London, GB, EC1M 6BQ
GB Newcastle Upon Tyne, GB, NE7 7DN
KR Seoul, KR, 06351
KR Seoul, KR, 03722
KR Seoul, KR, 03080
SE Lund, SE, 22185
SE Stockholm, SE, 118 83
US, CA La Jolla, CA, US, 92093
US, CA Los Angeles, CA, US, 90095
US, CA San Francisco, CA, US, 94143
US, IL Chicago, IL, US, 60611
US, MA Boston, MA, US, 02215
US, NY New York, NY, US, 10065
US, NY New York, NY, US, 10040
US, OR Portland, OR, US, 97239
US, TX Houston, TX, US, 77030
US, VA Richmond, VA, US, 23298